Tech Observer - the Global CRO participated in ILSI-Biomed 2011...

Tech Observer - the Global CRO participated in ILSI-Biomed 2011...

May 23-25, 2011 - ILSI Biomed 2011 Conference

Tech Observer - the Global CRO participated in ILSI-Biomed 2011 Conference held May 23-25, 2011 in Tel-Aviv. The conference was a meeting place for industry and academia from Israel and abroad.

The agenda with thought-provoking content that was both relevant and directly related to science and innovations in the medical field. With the future of the industry viewed as challenging, aim was to encourage “out-of-the-box” thinking, call for courageous actions, all for the purpose of promoting thriving innovation.

ILSI-Biomed 2011 follows the success of previous annual conferences: last year’s event drew 6,000 industry players, engineers and scientists, with 1,000 participants from 42 countries and in excess of 2,500 one-on-one meetings.

This year’s conference was featured a rich program and supporting events:

  • A full day Cardiovascular Symposium and seminars focusing on the patient of tomorrow, preventative medicine, oncology, orphan diseases, CNS diseases, and regulation/reimbursement
  • 60 presentations given by Israeli medical device and biopharma companies
  • Cutting-edge keynote addresses by prominent industry leaders from Israel and abroad
  • A platform where science, technology, academia and industry come together
  •  Present up-to-date issues around the economical and regulatory landscape and the future of healthcare through a variety of panels on industry topics and trends
  • Provide a meeting place for personalized one-on-one meetings and networking opportunities
  • Start-up Pavilion where a wealth of innovation is displayed

 

Name of few key Speakers:

 Kenneth S. Abramowitz, Managing General Partner and co-founder of NGN Capital

Dr.  David L. Brown, MD, Co-Founder of the Heart Hospital Baylor in Plano, Texas

Alastair Clemow,  President and CEO of Regentis Biomaterials

Barry Greene, President and Chief Operating Officer of Alnylam Pharmaceuticals

Dr. Charlotte Kremer, VP Specialty Neuroscience in the Specialty Care Business Unit at Pfizer, New York

Dr.  Hugo Vanermen M.D., FETCS., Head, Department of Cardiovascular & Thoracic Surgery at Onze-Lieve-Vrouw-Ziekenhuis

 

For media related or any other enquiries regarding press release, please contact:

Email: pr@tech-observer.com